Cancer Genetics' Focus::CLL
Cancer Genetics has launched Focus::CLL, a next-generation sequencing-based panel for chronic lymphocytic leukemia and small lymphocytic leukemia. The panel assesses seven genes with clinical relevance for prognosis, disease management, and treatment selection. It has an analytical sensitivity of 5 percent. Focus::CLL will be available as an individual test and will also be integrated into the company's Complete offerings for CLL and SLL. In addition, it will be available through Cancer Genetics' Select One clinical trials offering, which provides clinical trial support to biotech and pharmaceutical companies.